INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $25.82 per share for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-09-30 was 8.19 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2020-09-30 | 8.19 CAD/shares 10-Q · filed 2020-12-17 | |
| 2020-06-30 | 37.39 CAD/shares 10-Q · filed 2020-12-17 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.82 S-4/A · filed 2026-09-09 | |||
| 2026-03-31 | $56.29 S-4 · filed 2026-07-02 | |||
| 2025-12-31 | $244.11 10-Q · filed 2026-02-11 | |||
| 2025-09-30 | $7.40 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $70.43 S-4/A · filed 2026-09-09 | |||
| 2025-03-31 | $45.19 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $2866.46 10-Q · filed 2025-02-12 | |||
| 2024-06-30 | $3286.80 S-4 · filed 2026-07-02 | |||
| 2023-12-31 | $41942.00 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | $495.98 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $267.13 10-K · filed 2023-09-29 | |||
| 2022-06-30 | $122.38 10-K · filed 2023-09-29 | |||
| 2020-09-30 | $6.14 10-Q · filed 2020-12-17 | |||
| 2020-06-30 | $27.43 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |